Efficacy of 5 mg Olanzapine in the Prevention and Treatment of Carboplatin-Induced Nausea and Vomiting in the Chinese Population

To investigate the efficacy and safety of low-dose 5 mg olanzapine triple regimen for prevention of carboplatininduced nausea and vomiting in Chinese population. 56 patients with malignancies were treated with carboplatin (area under the curve≥5) chemotherapy. All patients received a triple antiemetic regimen of 5 mg olanzapine combined with 5-hydroxytryptamine-3 receptor antagonist and dexamethasone. The primary endpoint of the study was total control in the overall phase (0-120 h), acute phase (0-24 h) and delayed phase (25-120 h) in all patients. Secondary endpoints were total protection and complete response in the overall phase, acute phase and delayed phases. The impact of chemotherapy-induced nausea and vomiting on the quality of life was assessed by the functional living index-emesis. Olanzapine related side-effect was also recorded. The primary end points total control in the overall phase, acute phase and delayed phases were 62.50 % (35/56), 87.50 % (49/56) and 64.28 % (36/56) respectively. These end points total protection in the overall phase, acute phase and delayed phases were 82.14 % (46/56), 96.42 % (54/56) and 83.92 % (47/56) respectively. The complete response rate in the overall phase, acute phase and delayed phases were 91.07 % (51/56), 98.21 % (55/56) and 91.07 % (51/56) respectively. There was no effect on life-quality (score≥108) assessed by functional living index-emesis was 62.50 %.The most common olanzapine-related side effects were Grade I-II somnolence and weakness. The 5 mg olanzapine based triplet antiemetic regimen is effective and safe in the prevention carboplatin-induced nausea and vomiting in the Chinese population.